Ikarian Capital, LLC Protagonist Therapeutics, Inc Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $4.48 Million - $7.48 Million	319,000 New	319,000 $7.31 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $630,700 - $1.03 Million	35,000 New	35,000 $966,000
Q2 2020 Aug 14, 2020	SELL	$6.19 - $18.84 $979,394 - $2.98 Million	-158,222 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$5.4 - $9.22 $431,438 - $736,641	79,896 Added 102.0%	158,222 $1.12 Million
Q4 2019 Jan 31, 2020	BUY	$4.69 - $13.45 $367,348 - $1.05 Million	78,326 New	78,326 $552,000

248

56.7M

76.3K

114K

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.